These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32799683)

  • 1. Therapeutic advances in Dravet syndrome: a targeted literature review.
    Strzelczyk A; Schubert-Bast S
    Expert Rev Neurother; 2020 Oct; 20(10):1065-1079. PubMed ID: 32799683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing Landscape of Dravet Syndrome Management: An Overview.
    Samanta D
    Neuropediatrics; 2020 Apr; 51(2):135-145. PubMed ID: 32079034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
    Guerrini R; Chiron C; Vandame D; Linley W; Toward T
    Epilepsia Open; 2024 Apr; 9(2):689-703. PubMed ID: 38427284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Lattanzi S; Trinka E; Russo E; Del Giovane C; Matricardi S; Meletti S; Striano P; Damavandi PT; Silvestrini M; Brigo F
    Drugs; 2023 Oct; 83(15):1409-1424. PubMed ID: 37695433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging drugs for the treatment of Dravet syndrome.
    Brigo F; Striano P; Balagura G; Belcastro V
    Expert Opin Emerg Drugs; 2018 Dec; 23(4):261-269. PubMed ID: 30482063
    [No Abstract]   [Full Text] [Related]  

  • 6. Stiripentol for the treatment of seizures associated with Dravet syndrome.
    Chiron C
    Expert Rev Neurother; 2019 Apr; 19(4):301-310. PubMed ID: 30900478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome.
    Schoonjans AS; Ceulemans B
    Expert Rev Neurother; 2022 May; 22(5):351-364. PubMed ID: 33455486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison.
    Devi N; Madaan P; Asrar MM; Sahu JK; Bansal D
    Seizure; 2021 Oct; 91():316-324. PubMed ID: 34274891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
    Nabbout R; Mistry A; Zuberi S; Villeneuve N; Gil-Nagel A; Sanchez-Carpintero R; Stephani U; Laux L; Wirrell E; Knupp K; Chiron C; Farfel G; Galer BS; Morrison G; Lock M; Agarwal A; Auvin S;
    JAMA Neurol; 2020 Mar; 77(3):300-308. PubMed ID: 31790543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances in the Drug Treatment of Dravet Syndrome.
    Wirrell EC; Nabbout R
    CNS Drugs; 2019 Sep; 33(9):867-881. PubMed ID: 31549357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment-Refractory Dravet Syndrome: Considerations for Novel Medications.
    Lopez JC; Pare JR; Blackmer AB; Orth LE
    J Pediatr Health Care; 2022; 36(5):479-488. PubMed ID: 35987555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stiripentol for the treatment of seizures in Dravet syndrome.
    Eschbach K; Knupp KG
    Expert Rev Clin Pharmacol; 2019 May; 12(5):379-388. PubMed ID: 31017478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
    Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
    Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.
    Zhang L; Li W; Wang C
    Acta Neurol Scand; 2021 Apr; 143(4):339-348. PubMed ID: 33336426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
    Lagae L; Sullivan J; Knupp K; Laux L; Polster T; Nikanorova M; Devinsky O; Cross JH; Guerrini R; Talwar D; Miller I; Farfel G; Galer BS; Gammaitoni A; Mistry A; Morrison G; Lock M; Agarwal A; Lai WW; Ceulemans B;
    Lancet; 2019 Dec; 394(10216):2243-2254. PubMed ID: 31862249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine.
    Zhang Y; Kecskés A; Copmans D; Langlois M; Crawford AD; Ceulemans B; Lagae L; de Witte PA; Esguerra CV
    PLoS One; 2015; 10(5):e0125898. PubMed ID: 25965391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.
    Strzelczyk A; Schubert-Bast S
    CNS Drugs; 2022 Mar; 36(3):217-237. PubMed ID: 35156171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.
    Villanueva V; Carreño-Martínez M; Gil Nagel-Rein A; López-González FJ
    Rev Neurol; 2021 Apr; 72(S01):S1-S10. PubMed ID: 33908026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stiripentol: A Review in Dravet Syndrome.
    Frampton JE
    Drugs; 2019 Nov; 79(16):1785-1796. PubMed ID: 31617141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.